Angiogenesis and cancer: From biopathology to therapy;Angiogénese e cancro: Da biopatologia à terapêutica

Acta Medica Portuguesa

Volumn 17, Issue 1, 2004, Pages 76-93

  Graça, Bruno ^a   Lunet, Carla ^a   Coelho, Ana Sofia ^a   Monteiro, Gisela ^a   Freire, Paulo ^a   Speidel, Andreia ^a   Carvalho, Lina ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Angiogenesis; Breast carcinoma; Colo rectal carcinoma; Gastric cancer; Lung carcinoma; Sarcoma

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BATIMASTAT; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; EFLORNITHINE; ENDOSTATIN; FLUOROURACIL; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; INTERLEUKIN 8 ANTIBODY; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN P53; RETINOID; SEMAXANIB; TAMOXIFEN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; CANCER; CANCER GRADING; CANCER GROWTH; COLORECTAL CARCINOMA; GENE MUTATION; HUMAN; LUNG CANCER; METASTASIS; REVIEW; SARCOMA; STOMACH CANCER; VALIDATION PROCESS;

CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; HUMANS; LUNG NEOPLASMS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SARCOMA; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 9644300820     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. a edição. Lippincott Williams & Wilkins. New York. 2001
2. BRAUNWALD E, FAUCI A, KASPER D et al: Harrison's Principles of Internal Medicine - cap 83. 15° edição. McGraw-Hill, New York. 2001
3. a edição. WB Saunders. Philadelphia. 1999
4. DOMINICI M, CAMPIONI D, LANZA F, et al: Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features. Leukemia 2001;15(1):171-176
5. RAJKUMAR SV, FONSECA R, WITZIG TE, GERTZ MA, GREIPP PR: Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 1999;13(3):469-472
6. VACCA A, RIBATTI D, RUCO L, et al: Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. British Journal of Cancer 1999;79(5-6):965-970
7. AUDERO E, CASCONE I, ZANON I: Expression of angiopoietin-1 in human glioblastomas regulates tumor-induced angiogenesis: in vivo and in vitro studies. Arteriosclerosis, Thrombosis & Vascular Biology 2001;21(4):536-541
8. AHMAD SA, LIU W, JUNG YD, et al: Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer, 2001;92(5):1138-1143
9. NEEMAH M, PROVENZALE JM, DEWHIRST MW: Magnetic resonance imaging applications in the evaluation of tumor angiogenesis. Seminars in Radiation Oncology, 2001;11(1):70-82
10. IMADA A, SHIJUBO N, KOJIMA H, ABE S. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. European Respiratory Journal, 2000;15(6):1087-1093
11. TAKANAMI I, TAKEUCHI K, NARUKE M: Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 2000;88(12):2686-2692
12. EEROLA AK, SOINI Y, PAAKKO P: Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma. Lung Cancer 1999;26(2):73-83
13. NISHIE A, ONO M, SHONO T, et al: Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clinical Cancer Research 1999;5(5):1107-1113
14. RIEDEL F, GOTTE K, SCHWALB J, SCHAFER C, HORMANN K: Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck. Acta Oto-Laryngologica 2000;120(1):105-111
15. SANZ-ORTEGA J, STEINBERG SM, MORO E: Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histology & Histopathology 2000;15(2):455-62
16. KONDO Y, ARII S, FURUTANI M, et al: Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma. Cancer 2000;88(8):1820-1827
17. CHIBA Y, TANIGUCHI T, MATSUYAMA K, et al: Tumor angiogenesis, apoptosis, and p53 oncogene in stage I lung adenocarcinoma. Surgery Today 1999;29(11):1148-53
18. GIATROMANOLAKI A, STATHOPOULOS GP, TSIOBAHOU E, et al: Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999;86(8):1421-1430
19. ALVAREZ AA, AXELROD JR, WHITAKER RS, et al: Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Gynecologic Oncology 2001;82(2):273-278
20. OZER E, OZKAL S, KARADEMIR S, et al: Angiogenesis and p53 and H-ras mutations in pancreatic ductal adenocarcinoma. Analytical & Quantitative Cytology & Histology 1999;21(6):473-476
21. OH-E H, TANAKA S, KITADAI Y, SHIMAMOTO F, YOSHIHARA M, HARUMA K: Angiogenesis at the site of deepest penetration predicts lymph node metastasis of submucosal colorectal cancer. Diseases of the Colon & Rectum 2001;44(8):1129-1136
22. TIEN YW, CHANG KJ, JENG YM, et al: Tumor angiogenesis and its possible role in intravasation of colorectal epithelial cells. Clinical Cancer Research 2001;7(6):1627-1632
23. ZHANG X, KONG C, TAKEHAKA I: Evaluation of cell proliferation, apoptosis, and angiogenesis in transitional cell carcinoma of the renal pelvis and ureter Urology 2001;57(5):981-985
24. BRAYBROOKE JP, O'BYRNE KJ, PROPPER DJ, et al: A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clinical Cancer Research 2000;6(12):4697-4704
25. ERENOGLU C, AKIN ML, ULUUTKU H, TEZCAN L, YILDIRIM S, BATKIN A: Angiogenesis predicts poor prognosis in gastric carcinoma. Digestive Surgery 2000;17(6):581-586
26. MACLEAN AB, REID WM, ROLFE KJ, et al: Role of angiogenesis in benign, prem alignant and malignant vulvar lesions. Journal of Reproductive Medicine 2000;45(8):609-612
27. KUROI K, TOI M: Circulating angiogenesis regulators in cancer patients. International Journal of Biological Markers 2001;16(1):5-26
28. YUAN A, YANG PC, YU CJ, et al: Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. American Journal of Respiratory & Critical Care Medicine 2000;162(5):1957-1963
29. VALTOLA R, SALVEN P, HEIKKILA P, et al: VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. American Journal of Pathology 1999;154(5):1381-1390
30. VORAVUD N, CHARURUK N: Tumor angiogenesis. Journal of the Medical Association of Thailand 1999;82(4):394-404
31. MARIA WONG, NGAI CHEUNG, SIU T YUEN, SUET Y LEUNG AND L PING CHUNGET: Vascular endothelial growth factor is upregulated in the early pre-malignant stage of colorectal tumour progression. International Journal of Cancer 1999;81:845-850
32. WERTHER K, CHRISTENSEN IJ, BRUNNER N, NIELSEN HJ, DANISH R: Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Study Group. European Journal of Surgical Oncology 2000;26(7):57-662
33. THIERRY ANDRÉ, LARISSA KOTELEVETS, JEAN CRISTOPHE VAILLANT, et al: VEGF, VEGF-B, VEGF-C, and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. International Journal of Cancer 2000;86:174-181
34. TOKUNAGA T, OSHIGA Y, ABE Y, OZEKI Y, Vascular endothelial growth factor (VEGF)mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. British Journal of Cancer 1998;77(6):998-1002
35. SHAHEEN RM, TSENG WW, VELLAGAS R, et all: Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tum or vascularity, and apoptosis in a murine model of colon carcinomatosis. International Journal of Oncology 2001;18(2):221-226
36. YUTAGA TAKAHASHI, CORAZON D. BUCANA, KAREN R.CLEARY, LEE M. ELLIS: p53, vessel cunt, and vascular endothelial growth factor expression in human colon cancer. International Journal of Cancer 1998;79:34-38
37. AHMAD SA, LIU W, JUNG YD, FAN F, REINMUTH N, BUCANA CD, ELLIS LM: Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma, A possible mechanism for the initiation of angiogenesis. Cancer 2001;92:1138-1143
38. MAEDA K, NISHIGUCHI Y, KANG S, et al: Expression of trombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncology Reports 2001;8(4):763-766
39. TOKUNAGA T, OSHIGA Y, NAKAMURA M, et al: Trombospondin-2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. British Journal of Cancer 1999;79(2):354-359
40. KAWAKAMI T, TOKUNAGA T, HATANAKA E, et al: Interleukin 10 expression is correlated with trombospondin expression and decreased vascular involvement in colon cancer. International Journal of Oncology 2001;18(3):487-491
41. MICHAEL BOUVET, LEE M, NISHIZAKI M, et al: Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibitis angiogenesis in human colon cancer. Cancer Research 1998;58:2288-2292
42. HIROKI K, WATARU Y, HISASHI SHINOHARA, et al: Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. American Journal of Pathology 2000;157(5):1523-1535
43. SHAHEEM R, AHMAD S, LIU W, et al: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. British Journal of Cancer 2001;85(4):584-589
44. SCHWARTZ, et al: Princípios de Cirurgia, compẽndio- cap. 16. MC Graw Hill.Rio de Janeiro, 2000
45. MARIA TERESA MAGALHÃES GODINHO; C.Alves Pereira-Cirurgia, Patologia e Clinica-cap. 17.MC Graw Hill. Lisboa, 1999
46. ADI F. GAZDAR, JOHN D. MINNA: Angiogenesis and the Multistage Development of Lung Cancers. Clinical Cancer Research 2000;6:1611-1612
47. KEITH et al: Angiogenic Squamous dysplasia in bronchi of individuals at high rise for lung cancer. Clinical Cancer Research 2000;6:1616-1625
48. G. COX, J.L. JONES, R.A. WALKER, W.P. STEWARD, K.J: O'Byrne. Angiogenesis and non-small cell lung cancer. Lung Cancer 2000;27:81-100
49. T. YANO, S. TANIKAWA, T. FUJIE, M. MASUTANI, T. HORIE: Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. European Journal of Cancer 2000;36:601-609
50. YAMASHITA J, OGAWA M, ABE M, NISHIDA M: Platelate-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer. Chest 1999;116(1):206-211
51. YUAN A, YANG P C, YU C J, et al: IL-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in NSCLC. American Journal of Respiratory & Critical Care Medicine.2000;162(5):1957-1963
52. WONG M P, CHAN SY, FU KH, et al: The Angiopoietins, tie 2 and Vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer.2000;29(1):11-22
53. BOLDRINI L, CALCINAI A, SAMARITANI E, et al: Tumour necrosis factor-alpha and transforming growth factor- beta, are significantly associated with better prognosis in Non-Small Cell lung carcinoma: putative relation with bcl-2-mediated neovascularization. British Journal of Cancer.2000;83(4):480-486
54. BIRGITTE V. OFFERSEN, PER PFEIFFER, STEPHEN HAMILTON-DUTOIT, JENS OVERGAARD: Patterns of Angiogenesis in Nonsmall-Cell Lung Carcinomoma. American Cancer Society 2001;91:1500-1509
55. PHILLIPS P G, BIRNBY LM, NARENDRAN A, MILONOVICH WL: Nitric Oxide modulates capillary formation at the endothelial cell-tumour cell interface. American Journal of Physiology - Lung celular & molecular.2001;281(1):278- 290
56. GABRIELLA FONTANINI, LAURA BOLDRINI, ALESSANDRA CALCINAI, et al: Thrombospondins I and II Messenger RNA Expression in Lung Carcinoma: Relationship with p53 Alterations, Angiogenic Growth Factors, and Vascular Density. Clinical Cancer Research.1999;5:155-161
57. VOLM M, MATTERN J, KOOMAGI R: Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis and patient survival. Oncology Reports 1999;6(3):611-615
58. UEFUJI K, ICHIKURA T, MOCHIZUKI H: Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clinical Cancer Research 2000;6(1):135-138
59. TSUJI S, TSUJII M, KAWANO S, HORI M: Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis. Journal of Experimental & clinical Cancer Research 2001;20(1):117-129
60. KONTUREK PC, HARTWICH A, ZUCHOWICZ M, et al: Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer. Journal of Physiology & Pharmacology 2000;51(4Pt1):737-749
61. OGAWA K, KONNO S, TAKEBATASHI T, et al: Effect of intratumoral OK-432 administration of thymidine phosphorylase expression in human gastric carcinoma. Anticancer Research 2001;21(2B): 1257-1202
62. GIATROMANOLAKI A, KOUKOURAKIS MI, STATHOPOULOS GP, et al: Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorilase, and p53 protein expression in locally advanced gastric cancer. Oncology Research 2000;12(1):33-41
63. KIKUYAMA S, INADA T, SHlMIZU K, MIYAKITA M: Thymidine phosphorilase expression in gastric cancer in association with proliferative activity and angiogenesis. Anticancer Research 2000;20(3B):2081-2086
64. ETOH T, INOUE H, TANAKA S, BARNARD GF, KITANO S, MORI M: Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via indution of proteases. Cancer Research 2001;61(5):2145-2153
65. KIMURA H, KONISHI K, NUKUI T, et al: Prognostic significance of expression of thymidine phosphorilase and vascular endothelial growth factor in human gastric carcinoma. Journal of Surgical Oncology - Supplement 2001;76(1):31-36
66. KITADAI Y, TAKAHASHI Y, HARUMA K, et al: Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. British Journal of Cancer 1999;81(4):647-653
67. TAHARA E: Molecular aspects of invasion and metastasis of stomach cancer. Verhandlungen der Deutschen Gesellschaft fur Pathologie 2000;84:43-49
68. KOIDE N, NISHIO A, IGARASHI J, KAJIKAWA S, ADAOHI W, AMAHO J: Alpha-fetoprotein-producing gastric cancer: histochemical analysis of cell proliferation, apoptosis, and angiogenesis. American Journal of Gastroenterology 1999;94(6):1658-1663
69. LEE JH, KOH JT, SHIN BA, et al: Comparative study of angistatic and anti-invasive gene expression as prognostic factors in gastric cancer. International Journal of Oncology 2001;18(2):355-301
70. KIM YB, HAN JY, KIM TS, KIM PS, CHU YC: Overexprsssion of c-H-ras p21 is correlated with vascular engothelial growth factor and neovascularization in advanced gastric carcinoma. Journal of Gastroenterology & Hepatology 2000;15(12):1393-1399
71. TSUTSUMI S, KUWANO H, ASAO T, NAGASHIMA K, SHIMURA T, MOCHIKI E: Expression of Ets-1 angiogenesis-related protein in gastric cancer. Cancer Letters 2000;160(1):45-50
72. SHIN EY, LEE BH, YANG JH, et al: Up-regulaticn and co-expression of fibroblast growth factor receptors in human gastric cancer. Journal of Cancer Research & Clinical Oncology 2000;126(9):519-528
73. LIN HL, LIU TY, WU CW, CHI CW: 2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G(2)/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer 2001;92(3):500-509
74. TAKAHASHI Y, MAI M, NISHIOKA K: alpha-difluoromethylomithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model. International journal of Cancer 2000;85(2):243-247
75. HANSEN S, GRABAU DA, SORENSEN FB, BAK M, VACH W, ROSE C: The prognostic value of angiogenesis by Chalkley counting in confirmatory study deaing on 836 breast cancer patients. Clinical Cancer Research 2000;6(1):139-146
76. HEIMANN R, LAN F, MCBRIDE R, HELLMAN S: Separating favourable from unfavoreble prognostic markers in breast cancer: the role of E-cadherin. Cancer Research 2000;60(2):298-304
77. JITSUIKI Y, HASEBE T, TSUDA H, et al: Optimizing microvessel counts according to tumor zone in invasive ductal carcinoma of the breast. Modern Pathology 1999;12(5):492-498
78. GAEPARINI G: Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Critical Reviews in Oncology-Hematology 2001;37(2):97-114
79. GASPARINI G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000;5 Suppl 1:37-44
80. CALLAGY G, DIMITRIADIS E, HARMEY J, BOUCHIER-HAYES D, LEADER M, KAY E: Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than micro-vessel density or serum vascular endothelial growth factor. Applied Immunohistochemistry & Molecular Morphology 2000;8(2):104-109
81. LINDERHOLM B, LINDH B, TAVELIN B, GRANKVIST K, HENRIKSSON R: p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. International Journal of Cancer 2000;89(1):51-62
82. GUNNINGHAM SP, CURRIE MJ, HAN C, et al: VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. Journal of Pathology 2001;193(3):325-332
83. KUREBAYASHI J, OTSUKI T, KUNISUE H, et al: Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Japanese Journal of Cancer Research 1999;90(9):977-981
84. YANG Q, SAKURAI T, YOSHIMURA G, et al: Thymidine phosphorylase expression correlates with tumor differentiation and Bcl-2 in invasive breast cancer. Breast Cancer 2000;7(3):210-214
85. LEE AH, DUBLIN EA, BOBROW LG: Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast. Journal of Pathology 1999;187(3): 285-290
86. SMITH K, FOX SB, WHITEHOUSE R, et al: Upregulation of basic fibroblast growth factor in breast carcinoma, and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Annals of Oncology 1999;10(6):707-713
87. GUIDI AJ, BERRY DA, BROADWATER G, et al: Association of angiogenesis in lymph node metastases with outcome of breast cancer. Journal of the National Cancer Institute 2000;92(6):486-492
88. COLPAERT C, VERMEULEN P, JEURIS W, et al: Early distant relapse in "no de-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. Journal of Pathology 2001;193(4):442-449
89. KAKOLYRIS S, FOX SB, KOUKOURAKIS M, et al: Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. British Journal of Cancer 2000;82(4):844-851
90. LI C, GUO B, WILSON PB, et al: Plasma, levels of soluble CD105 correlate with metastasis in patients with breast cancer. International Journal of Cancer 2000;89(2):122-126
91. KNOPP MV, WEISS E., SINN HP, et al: Pathophysiologic basis of contrast enhancement in breast tumors. Journal of Magnetic Resonance Imaging 1999;10(3):260-266
92. HAN S, KIM JS, KIM BS, KOH IH, PARK K: 99mTc-MIBI scan in mammary Pagets disease: a case report. Journal of Korean Medical Science 1999;14(6):675-678
93. YOON JH, BOM HS, SONG HC, LEE JH, JAEGAL TJ: Double-phase Tc-99m sestamibi scintimammography to assess angiogenesis and P-glycoprotein expression in patients with untreated breast cancer. Clinical Nuclear Medicine 1999;24(5):314-318
94. VIENS P, JACQUEMIER J, BARDOU PJ, et al: Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy. Breast Cancer Research & Treatment 1999;54(3):205-212
95. GASPARINI G, TOI M, MICELI R, et al: Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer Journal From Scientific American 1999;5(2):101-111
96. TOI M, BANDO H, KUROI K: The predictive value of angiogenesis for adjuvant therapy in breast cancer. Breast Cancer 2000;7(4):311-314
97. MARSON LP, KURIAN KM, MILLER WR, DIXON JM: The effect of tamoxifen on breast tumour vascularity. Breast Cancer Research & Treatment 2001;66(1):9-15
98. KUROI K, TANAKA C, TOI M: Circulating levels of endostatin in cancer patients. Oncology Reports 2001;8(2):405-409
99. GOFFIN V, TOURAINE P, PICHARD C, BERNICHTEIN S, KELLY PA: Should prolactin reconsidered as a therapeutic target in human breast cancer?. Molecular & Celular Endocrinology 1999;151(1-2):79-87
100. GREB RR, MAIER, WALLWIENER D, KIESEL L: Vascular endothelial growth factor A (VEGF-A) mRNA expression levels decrease after menopause in normal breast tissue but not in breast cancer lesions. British Journal of Cancer 1999;81(2):255-231
101. HYDER SM, CHIAPPETTA C, STANCEL GM: Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. International Journal of Cancer 2001;92(4):469-473
102. CHAO C, ALSALEEM T, BROOKS JJ, ROGATKO A, KRAYBILL WG, EISENBERG B: Vascular endothelial growth factor and soft tissue sarcomas: Tumor expression correlates with grade. Annals of Surgical Oncology. 2001;8(3):260-267
103. IYODA A, HIROSHIMA K, BABA M, FUJISAWA T, YUSA T, OHWADA H: Expression of vascular endothelial growth factor in thoracic sarcomas. Annals of Thoracic Surgery. 2001;71(5):1635-1639
104. KAWAUCHI S, FUKUDA T, TSUNEYOSHI M: Angiogenesis does not correlate with prognosis of expression of vascular endothelial growth factor in synovial sarcomas. Oncol Rep 1999;6(5):959-964
105. MENTZEL T, BROWN LF, DVORAK HF, et al: The association between tumos progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Archiv. 2001;438(1):13-22
106. HANDA A, TOKUNAGA T, TSUCHIDA T, LEE YH, KIJIMA H, YAMAZAKI E, UEYAMA Y, FUKUDA H, NAKAMURA M: Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma. International Journal of Oncology. 2000;17(2):291-295
107. MANTADAKIS E, KIM G, REISCH J et al: Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma. Journal of Pediatric Hematology Oncology. 2001;23(5):286-289
108. GRAEVEN U, ANDRE N, ACHILLES E, ZORNIG C, SCHMIEGEL W: Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft tissue sarcoma. Jornal of Cancer Research & Clinical Oncology, 1999;125(10):577-581
109. TEMMIN L, KOLLE S, BAKER H, SINOWATZ F: Expression of growth hormone receptor in human liposarcomas and lipomas. Oncology Reports. 2000;7(4):757-760
110. LEVINE AM, TULPULE A: Clinical aspects and management of AIDS related Kaposi's sarcoma. European Journal of Cancer. 2001;37 (10):1288-1295
111. ARASTEH K, HANNAH A: The role of vascular endothelial growth factor (VEGF) in AIDS-related Karposi's sarcoma. Oncologist. 2000;5 Suppl 1:28-31
112. BARILLARI G, SGADARI C, PALLADINO C, et al.: Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angionesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. Journal of Immunology. 1999;136(4): 1929-1935
113. ASCHERL G, SGADARI C, BUGARINI R, BOGNER J, SCHATZ O, ENSOLI B, STURZL M: Serum concentrations of fibroblast growth factor 2 are increased in HIV type 1-infected patients and inversely related to survival probability. AIDS Research & Human Retroviruses, 2001;17(11):1035-1039
114. KARP JUDITH E, GOOPMAN JEROME E, BRODER SAMUEL: Cancer: Principles and Practise of Oncology, 4th Ed, edited by De Vita Vincent T Jr, Hellman Samuel, Rosenberg Steven A. Lippincott J.B., Philadelphia 1993, Chapter 59, Cancer in AIDS, pg. 2094-2096
115. TULPULE A, SCADDEN DT, ESPINA BM, CABRIALES S, HOWARD W, SHEA K, GILL PS: Results of a randomizes study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. Journal of Clinical Oncology. 2000;18(4):716-723
116. TARABOLETTI G, BENLLI R, BORSOTTI P, RUSNATI M, et al: Thrombosondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogensis and is poorly expressed in KS lesions. Journal of Pathology. 1999;188(1):76-81
117. LITTLE RF, WYVILL KM, PLUDA JM et al.: Activity of thalidomide in AIDS-related Kaposi's sarcoma. Journal of Clinic Oncology. 2000;18(13):2593-2602